Cargando…
CSF IL-8 Associated with Response to Gene Therapy in a Case Series of Spinal Muscular Atrophy
Gene therapies have greatly changed the outlook in spinal muscular atrophy (SMA), and this disorder provides a rare opportunity to study longitudinal biomarker changes correlated with reduced disease burden and improved clinical outcomes. Recent work suggests clinical response to correlate with decl...
Autores principales: | Verma, Sumit, Perry, Kelsey, Razdan, Raj, Howell, J. Christina, Dawson, Alice L., Hu, William T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607706/ https://www.ncbi.nlm.nih.gov/pubmed/36289175 http://dx.doi.org/10.1007/s13311-022-01305-9 |
Ejemplares similares
-
Advances and limitations for the treatment of spinal muscular atrophy
por: Day, John W., et al.
Publicado: (2022) -
Euglycemic Ketoacidosis in Spinal Muscular Atrophy
por: Stoimenis, Dimitrios, et al.
Publicado: (2019) -
Spinal muscular atrophy
por: D'Amico, Adele, et al.
Publicado: (2011) -
Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen
por: Wurster, Claudia D., et al.
Publicado: (2019) -
Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018)